AI Bio Optimism
Recursion is rallying sharply as broader artificial intelligence breakthroughs in biological discovery and multi-year data licensing partnerships bolster confidence in its drug discovery product engine.
Sources: https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH0aHVHrTZl2hEyA484wVO0ogIW4W5clpHysq-Og3E2Tum3n_JKvXEDl_a-wdKjGAcm05UvI5MSNKr7
Sources
Ezbrisk weighs each event against the market reaction and publishes a verdict with an overreaction reading. How the methodology works